Business Wire

​​​First and only EGFR inhibitor and targeted treatment to show benefit in Stage III setting, extending progression-free survival by more than three years

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal... (continue reading...)

• The results include data from three main study cohorts: In the non-squamous non-small cell lung cancer (NSCLC) cohort, an Objective Response Rate (ORR) for NSCLC of 19.0% (4/21), with 2 Partial Responses (PR) and 2 Complete Responses (CR) was observed. In the UC cohort, the ORR was 19.2% (5/26), with 4 PRs and 1 CR. In HCC, data from the first 20 patients showed an ORR of 20.0% (4/20), with 3 PRs and 1 CR in the early readouts.
• Exceptional Duration of Response... (continue reading...)

• DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement in primary endpoint of progression-free survival (PFS)
• Median PFS not yet reached at 21.8 months median follow-up versus 12.7 months in bortezomib combination
• Second trial to show robust efficacy for a belantamab mafodotin combination versus a standard of care in second line and later relapsed/refractory multiple myeloma
• Results simultaneously published in the New... (continue reading...)

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, human epidermal growth factor receptor 2-negative (HER2-negative), hormone receptor-positive metastatic breast cancer (TBCRC 041; ... (continue reading...)

CHICAGO--(BUSINESS WIRE)-- Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify patients with HER2 or FOLR1 expressing tumors, which may make such patients eligible for targeted therapies such as antibody–drug conjugates (ADCs). HER2 and FOLR1 testing by immunohistochemistry (IHC) is now available for all solid tumor cancers as an add-on to the company’s xT or xR next-generation... (continue reading...)